Get the Stockscreener App
2.6099
0.58%
0.0299
Century Therapeutics Inc stock is traded at $2.6099, with a volume of 1.58M.
It is up +0.58% in the last 24 hours and up +139.17% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$2.58
Open:
$2.55
24h Volume:
1.58M
Relative Volume:
0.88
Market Cap:
$228.13M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-1.1397
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+35.16%
1M Performance:
+139.17%
6M Performance:
+314.80%
1Y Performance:
+196.64%
1-Day Range:
$2.40
$2.71
1-Week Range:
$1.81
$2.71
52-Week Range:
$0.3418
$2.71
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.61 | 225.51M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.94 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.19 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.84 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.23 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.08 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics (IPSC) upgraded to strong buy: Here's what you should know - MSN
Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split - TipRanks
How sensitive is Century Therapeutics Inc to inflationQuarterly Portfolio Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deep Track Capital, LP's Strategic Acquisition of Century Therap - GuruFocus
Century Therapeutics stock price target raised to $4 from $2 at Piper Sandler - Investing.com India
Will Century Therapeutics Inc. stock deliver long term returnsTrend Reversal & Reliable Price Action Trade Plans - bollywoodhelpline.com
Big Money Moves: Will Century Therapeutics Inc benefit from seasonalityJuly 2025 Trends & Weekly Breakout Watchlists - baoquankhu1.vn
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Rises By 32.1% - MarketBeat
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.40 - Defense World
Century Therapeutics, Inc Updates on Pipeline and Clinical Progress - TradingView — Track All Markets
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Century Therapeutics (NASDAQ:IPSC) Upgraded at Zacks Research - Defense World
Century Therapeutics: Is This Stem Cell Stock Taking Root In 2026? - RTTNews
Is Century Therapeutics Inc. stock supported by strong cash flowsWeekly Trading Summary & Free Technical Pattern Based Buy Signals - Улправда
Can Century Therapeutics Inc. stock outperform in 2025 bull marketMarket Performance Summary & Expert Verified Stock Movement Alerts - ulpravda.ru
Century Therapeutics Inc. (IPSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How strong is Century Therapeutics Inc. stock revenue growthOil Prices & Stepwise Swing Trade Plans - ulpravda.ru
Can Century Therapeutics Inc. stock surprise with earnings upsidePortfolio Return Summary & AI Forecasted Stock Moves - Улправда
Century Therapeutics Inc.: Is an Upswing Approaching? - StocksToTrade
Century Therapeutics wins $135M private placement (IPSC:NASDAQ) - Seeking Alpha
Will Century Therapeutics Inc. stock deliver better than expected guidanceEarnings Growth Summary & Trade Opportunity Analysis Reports - Улправда
Can Century Therapeutics Inc. stock reach $100 price target2025 Geopolitical Influence & Safe Swing Trade Setups - ulpravda.ru
Century Therapeutics stock price target lowered to $6.60 at Clear Street - Investing.com Canada
Is Century Therapeutics Inc. stock attractive after correctionJuly 2025 PreEarnings & Consistent Growth Stock Picks - Улправда
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aug Swings: What sentiment indicators say about Century Therapeutics Inc. stockTrend Reversal & Daily Chart Pattern Signals - Улправда
Why Century Therapeutics Inc. stock is rated strong buyTrade Entry Report & Weekly Market Pulse Updates - Улправда
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes - Investing News Network
Century Therapeutics: New Leadership Sparks Interest - timothysykes.com
Layoff Watch: Is Century Therapeutics Inc. stock attractive for income investors2025 Risk Factors & Verified Short-Term Plans - ulpravda.ru
Century Therapeutics secures $135 million in private placement By Investing.com - Investing.com India
Century Therapeutics secures oversubscribed $135 million private placement financing to support lead program, CNTY-813 - marketscreener.com
Century Therapeutics secures $135 million in private placement - Investing.com
Century Therapeutics Signs Multiple Financing Agreements - TradingView — Track All Markets
[8-K] Century Therapeutics, Inc. Reports Material Event | IPSC SEC FilingForm 8-K - Stock Titan
Big bet on type 1 diabetes: $135M backs potentially curative cell therapy - Stock Titan
Zacks Research Upgrades Century Therapeutics (NASDAQ:IPSC) to Strong-Buy - MarketBeat
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - sharewise.com
Century Therapeutics, Inc.Common Stock (NQ: IPSC - FinancialContent
Century Therapeutics (IPSC) price target decreased by 20.00% to 4.08 - MSN
Dow Theory LettersCentury Therapeutics, Inc.Common Stock (Nasdaq:IPSC) Detailed Stock Data - FinancialContent
Critical Analysis: EOM Pharmaceutical (OTCMKTS:IMUC) & Century Therapeutics (NASDAQ:IPSC) - Defense World
Why fast-paced mover Century Therapeutics (IPSC) is a great choice for value investors - MSN
Trend Report: Is Century Therapeutics Inc stock attractive after correctionJuly 2025 Update & Expert-Curated Trade Recommendations - moha.gov.vn
Street Watch: Why Century Therapeutics Inc stock is rated strong buyJuly 2025 Macro Moves & Safe Entry Trade Reports - moha.gov.vn
Chad Cowan Buys 58,060 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Century Therapeutics announces resignation of board member - TipRanks
Century Therapeutics Announces Board Resignation - TradingView — Track All Markets
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):